Delivery Order SPE2DB20D2104-SPE2DB25FMYNN
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) under a firm fixed price contract valued at $3,328.73. The award, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a competitive, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major pharmaceutical distributor providing critical medical supplies to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,376.00 to supply Gemtesa 75 mg tablets (90-count packaging) with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a delivery order valued at $75,373.59 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units). This firm fixed-price contract, awarded on August 11, 2025, represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The contract contains no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $8,009.57 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Gemtesa 75 mg tablets (90-unit quantity). This is a firm fixed-price, non-set-aside contract with a completion date of August 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, was competitively selected...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,900.70 to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg on August 15, 2025, with completion expected by August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $52,500.45. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $61,502.26. This non-set-aside competitive award is categorized as a delivery order, with an ultimate completion date of July 29, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,880.45 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The contract is executed as a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $45.5K delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,779.72 for 90 tablets of Gemtesa 75 mg on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMYNNDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,478.60 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 21, 2025, with a completion date of August 22, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued through AmerisourceBergen's comprehensive global pharmaceutical support vehicle with the DLA, which enables the company to supply a wide range of medications and medical supplies to support military healthcare systems. Gemtesa (mirabegron) is a medication used to treat overactive bladder and represents the type of specialty pharmaceutical product that AmerisourceBergen regularly delivers through its federal contracts. The award reflects AmerisourceBergen's capability to fulfill federal medical supply requirements through open competition, as evidenced by its extensive portfolio of delivery orders across multiple therapeutic domains serving the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.5k | 8/21/25 |